Bunse, Lukas http://orcid.org/0000-0002-4490-7574
Rupp, Anne-Kathleen
Poschke, Isabel
Bunse, Theresa
Lindner, Katharina
Wick, Antje
Blobner, Jens
Misch, Martin
Tabatabai, Ghazaleh
Glas, Martin
Schnell, Oliver
Gempt, Jens
Denk, Monika
Reifenberger, Guido
Bendszus, Martin
Wuchter, Patrick
Steinbach, Joachim P
Wick, Wolfgang
Platten, Michael
Funding for this research was provided by:
Deutsches Krebsforschungszentrum (AMPLIFY-NEOVAC)
Article History
Received: 3 April 2022
Accepted: 11 April 2022
First Online: 23 May 2022
Declarations
:
: The study was approved by the national regulatory authority (Paul-Ehrlich Institute, Germany) and the institutional review boards (Ethikkommissionen) at each initiated study site.
: Not applicable.
: T.B., M.P. and W.W. are inventors and patent-holders on ‘Peptides for use in treating or diagnosing IDH1R132H positive cancers’ (EP2800580B1). G.T. has served on advisory boards of AbbVie, Bayer, Boehringer Ingelheim, received consulting fees from AbbVie, Bayer; received speaker fees from Medac and Novocure; received travel grants from Novocure, Medac; received research grants from Roche Diagnostics and Medac. M.G. reports honoraria from Roche, Novartis, UCB, Abbvie, Daiichi Sankyo, Novocure, Bayer, Janssen-Cilag, Medac, Merck, Kyowa Kirin, travel support from Novocure and Medac, research grant from Novocure. J.S. has received honoraria for lectures, travel or advisory board participation from Abbvie, Medac, Med-Update, Roche, Novocure and Seagen since 2019. Pfizer and Merck reviewed the manuscript for medical accuracy only before journal submission. The authors are fully responsible for the content of this manuscript, and the views and opinions described in the publication reflect solely those of the authors.